Rethinking Pharmacy Economics to Improve Drug Affordability and Patient Access with Hayley Park, PharmD
17 minAudio
In this episode, Hayley Park, PharmD, Chief Pharmacy Officer at Blue Shield of California, discusses Pharmacy Care Reimagined, biosimilar adoption and strategies to lower prescription drug costs. She also explores pharmacy industry trends, California policy changes and the importance of aligning financial incentives with better patient outcomes.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
- Hello, everyone. This is Jacob Emerson with the - Becker's Payer Issues podcast. - I'm thrilled today to be joined by Haley - Park, who serves as senior vice president and - chief pharmacy officer at Blue Shield of California. - Haley, thank you very much for taking the - time to be with me on the podcast - today. - Hi, Jacob. Thank you for having me. It's - a pleasure to be here. Absolutely. And thanks - for taking the time to chat with us. - Before we get started, Haley, I know you're - new to your role and so... Or this - year at least. And so, - for our audience who might not be familiar
- with you, I'm hoping you could tell them - a little bit more about yourself, your background - in health care, and what it is that - you do today at Blue Shield of California. - Yeah. Thanks, Jacob. - So as you mentioned, I've been here for - about six months and super excited to have - joined the Blue Shield of California team. I'm - a pharmacist by training, and, I spent more - than twenty five years across retail pharmacy, - disease management, integrated health systems, and now, with - the health plan.
- And what's been really interesting is I've seen - what happens when we optimize for individual parts - of the health care system - and then what's possible when you start to - connect them all together. - The other really interesting - observation I've had is that the incentives - are very different depending on which seat at - the table you're at. - I've seen at retail how it's about prescription - volume - in hospitals, - rigorous medication oversight and a focus on turnover.
- And of course, - you know, our focus around PBMs at Blue - Shield of California and how they have some - very sophisticated tools to manage drug spending, - but often with incentives that don't necessarily align - with patients. - And that's really what drew me to Blue - Shield of California. As a not for profit - health plan, - we have the opportunity - to bring, - like, benefits of an integrated - care system to a much broader population and - not through ownership, - but through partnerships.
- Because the real measure, I think, of integration, - it's not how much of the system you - own, but how well the system actually works - together for the people that... And the members - that we serve. - Absolutely. And and let me follow-up with what - you just said there, Haley, in terms of, - the incentives - look different across the different types of organizations - that you're at in health care. And, you - know, we've been speaking with Blue Shield leaders - for years, - or last few years of about, - a a pharmacy model that was launched,
- a few years back to shift how prescription - drugs have traditionally been priced and delivered - within the industry. And so - maybe we could back up for a for - a second and have you tell our audience - who who isn't familiar with the the model, - the the basics of this approach - and and the results that you've seen, - since its since its launch. - Yeah. Absolutely. - And, - within our pharmacy care reimagined - initiatives, - what we've done is taken the traditional pharmacy
- benefit management model, which is typically - integrated. - So lots of different, - functionalities - are done by one company. - And, unfortunately, that is incredibly opaque. - And as a health plan, you have surprisingly - very little control over the economics. - So what we did through pharmacy care reimagined - is we changed the economics of pharmacy, - not just change who manages it. So there - was a lot of thought that went into - this. - One example that I'll bring up is the
- Humira biosimilar, - And the biosimilars - are, of course, - much lower priced than their brand. - And so when it became available, you would - naturally believe that there would be, - a very quick adoption to get to this - lower priced medication that was essentially clinically, you - know, similar - to, their brand. But what we saw was - adoption was really slow because preferring this biosimilar - could put,
- a significant portion of branded rebates at risk. - So you had to balance the economics. - So when you think about it, you finally - have competition, - but the rebate system could penalize us for - using it. - So when we announced our pharmacy care reimagine - model, it was a modular system in '23. - We launched it in '25. - And, what's great is that it's building upon - existing innovative partnerships that had been in place - for nearly a decade.
- The early results you had asked for, well, - today we're sitting at about an 85% - biosimilar - adoption rate, - and we were able to negotiate what began - at about $500 - in terms of a net price - compared to a list price for Humira of - $7,000, - so a significant reduction. - Another example is our partnership through Civica Script. - And here we targeted generic, - specialty - medications. - And this is not typically a place where
- rebates play. - But what we were able to see through - the partnership with Civica is a 41% - reduction in abiraterone, - which is a prostate cancer medication, - and a 64% - reduction for capsidabine, - which is an oral chemotherapy, - drug. - And, of course, we wanna lower the spend - because that's ultimately gonna lower premiums for employers - and members. - But another thing that I really think about - is that upfront discount that lowers the member's - cost share at the pharmacy counter.
- And so we're not just lowering drug costs, - we're also changing who benefits from the savings - and when those benefits occur. And that was - really important to me. And that's really some - amazing numbers you just cited there, Haley, especially - around the Humira and and, getting that cost - down to 7,000 plus price down to 500. - I wonder, you know, when we talk to - pharmacy health plan leaders from from around the - country, - right now we've been hearing from them - in talking about the pipeline of specialty medications
- and therapies, - especially as the years go on and and - trying to evolve their their benefits - and, trying to keep those medications, - accessible and affordable. - And so I wonder going off of what - you just... You laid out for us and - and, like I said, what we're hearing from - across the industry, what do you see in - some of the biggest trends shaping the pharmacy - industry right now, and and how does that - all, - play into what you all are trying to - do with Blue Shield of of keeping things - accessible and affordable, - under an evolving benefits model?
- Yeah. Jacob, there are so many forces right - now that are reshaping pharmacy, probably the biggest - amount of change that I've seen in my - entire career. - And the the the themes that I'm seeing - come up are around transparency, - around competition like we just talked about, - and a growing expectation, - especially as our spend is increasing, - that we demonstrate value. - So first, just around transparency. - Employers and patients, they're asking a pretty reasonable
- question, which is how how do the economics - work for what we're paying for? - What is the value that's coming back? - And, it's, - you know, it's... It can be confusing at - times when you have the same drug and - the same patient, and depending on where you - go to fill the medication, the price is - different. - So not a lot of transparency around how - all of this works with, - with the with the product. - The second is around competition. So we saw
- that biosimilars - and generics, they're creating lots of opportunity for - savings and affordability. - But just like I mentioned before, - because we have a lower cost treatment alternative - available, - it doesn't mean that our system is optimized - or designed to use it. So while we - have competition creating opportunity, - unless we change the incentives - with every part of the supply chain, - it's going to be very difficult to capture - its full value. - Just around competition and transparency,
- we're also seeing a lot of mid market - PBMs and alternative pricing models challenge the traditional - pricing and reimbursement. - And I think that's actually really healthy, - because just changing the players without changing the - incentives is not transformation. - And the third is value. And we can't - leave a pharmacy conversation without talking about the - GLP ones and all of the new cellular - and gene therapies that are coming in the - pipeline. - And we have these just remarkable innovations that - are coming, and they have tremendous clinical benefits.
- And we are looking to balance that with - affordability - and appropriate use. And I think this is - where health plans play an increasingly important role - of translating that clinical evidence in in partnership - with health systems and providers - into thoughtful coverage decisions. - Because the goal is not just to spend - less on medications, - we actually wanna get more health from every - dollar that we spend. - Absolutely. And I wonder, Haley, if you could - also speak to - broader affordability challenges and policy changes in California
- specifically - and how that's changing your approach to prescription - drug access. - You mentioned GLP ones, and we've obviously seen - a lot this year, at the federal level - trying to get GLP ones more affordable for - the Medicare population. So I wonder if you - could talk to the California version of that, - policy changes, - recently in the state or or, that you're - keeping an eye on that are shaping your - approach to prescription drug access. - Yeah. And I'm so glad you brought up
- the policies that have been changing both at - the federal level and then, of course, in - California. - And again, just a big recognition that it's - not just about lowering drug prices. - It's about making sure that the economics of - pharmacy actually work for employers and members. - So there have been a number of federal - reform bills that have gone through. - And in California, - one in particular that I would want to - highlight is SB ten ninety four, - where the focus is increasingly on transparency,
- accountability, - and removing the barriers that we have to - low cost medications. - And this is particularly relevant for biosimilars - where it addresses formulary access, - pharmacist substitution, - and then certain financial arrangements that can influence - which products the patients receive. - Because we've seen firsthand how rebate structures can - dis... Did they discourage biosimilar adoption even when - lower cost alternatives are available? - We believe this bill,
- will markedly - transform - the ability to convert patients to clinically equivalent, - biosimilar medications. - So we're excited about the new policies that - are coming through. - We know that we still have to protect - continuity of care because not every patient can - or should be switched simply because a less - expensive option exists. - And, I also believe we can't wait for - legislation to solve everything. - So through pharmacy care reimagined - and tools like price check myRx,
- we're taking everyday practical steps to improve transparency - and affordability for our members. - So excited about, SB ten ninety four, the - ability to convert to biosimilars - more easily and really bring that value back - to patients and our employers. - So, Haley, you're now just around six months, - in your role as chief pharmacy officer. And, - reflecting back on on your career experience coming - from some of the largest pharmacy organizations in - the country, some of the most high quality
- integrated medical systems in the country. - What are your top priorities at Blue Shield - of California for the year ahead? - Yeah. I love this question because it helps - to ground us on what is most important. - And for me, people always come first. - We, of course, need to deliver on performance. - And the third for for Blue Shield of - California right now is to ensure that we're - elevating pharmacy care. - When I think about people, this is not - just about the teams - that are just working so hard to bring,
- a health plan that is worthy of our - family friends to our members. - But it's also the members that we serve. - I wanna build a culture where every decision - starts with a member. That means empowering our - teams to think beyond their individual functions - and just really ask, how how does what - I'm doing today make health care better for - the people that we serve? - As a not for profit health plan at - Blue Shield of California, - I think I mentioned our mission is to - make health care worthy of our family and - friends and sustainably affordable.
- And we've seen this come through in our - engagement surveys that this truly is something that - is in the heart of our team members, - and how they work every day. - The second is around execution. We've made tremendous - progress with our pharmacy care reimagine model, but - we also know that launching the model is - just the beginning. - So we have these changes that we've made - and we've gained a lot of flexibility. - Now we have to deliver on that promise, - of affordability, - reliability, and a seamless member experience.
- I always say that, you know, members, they - don't experience our strategy. They experience whether their - pharmacy care works. - The third is the elevating pharmacy care. And - when I think about the practice of pharmacy, - the profession of pharmacy, - we know that, if you can connect clinical - pharmacy with members - and they are taking their medications appropriately, they - have an avenue to ask questions, that their - doses are getting titrated, - all of that is going to lead to - better care delivery. - And at Blue Shield of California, we're thinking
- about how do we do that through innovative - partnerships. - I've also seen firsthand the power of aligning - clinical care and financial incentives - through an integrated care and coverage, - model. - And I believe we can bring that to - more people. I ultimately want us to be - known for manage... Not just for managing pharmacy - costs, - but for making health care better for our - members. - Certainly. And I think it's a really great - line that your members might not know the - business strategy behind it all, but they certainly
- know, - what they experience - at the pharmacy counter. So I I think - where I wanna leave things, Haley, is having - you offer any final bits of advice or - final thoughts - to your pharmacy colleagues around the country who - are facing very similar challenges, if not the - same challenges all over the country. - And what you you would say to them, - as they also work to make prescription drugs - accessible to their members? Yeah. If - there's one thing I've learned over the years,
- it's that health care has no shortage of - just brilliant people with great intentions and innovative - ideas. - We see that come through with manufacturers who - are developing remarkable therapies, - providers - who wanna deliver great care, - and health plans who wanna keep health care - affordable. - So my advice is to think beyond the - boundaries - of your own organization. - Start with the patient outcome - that you're trying to achieve and work backward.
- Challenge the incentives - that may not be working for the entire - system and be willing to partner differently. - The goal isn't to prove our original idea - is right. It's to get the outcome right. - Because ultimately, our success should be measured not - just by what by what we save, - but but it's the health and the value - that we create for the people that we - serve. - I'm super excited again to be in pharmacy. - This is a great time - when we can redesign the health care system
- to really deliver on the promise of care - and compassion, - for every member and every human out there, - that really needs the support, - during what can be some of the toughest - times in in their life for themselves or - for the families and friends, - that surround them. - Wonderful. Well, Haley, I cannot thank you enough - for taking the time to chat with us - and for sharing your expertise with our listeners. - We really appreciate you doing so. - Thank you so much, Jacob, for having me
- today. - Yeah. Anytime. And to our listeners, if you'd - like to listen to more podcasts from Becker's - Healthcare, you can visit beckershospitalreview.com.
In this episode, Jon Grandstaff, Senior Vice President of Payment Integrity at Zelis, discusses how payers can reduce payment friction, use AI to support more accurate claims reviews and improve payer-provider...
In this episode, Amy Conlon, MPH, Population Health Sr. Manager at Exact Sciences, and Jeff Huebner, MD, FAAFP, Executive Medical Officer, Division of Medicaid Services, Wisconsin Department of Health Services, discuss...
In this episode, Denis Mrkva, Senior Vice President of Analytics Solutions at Data Axle, discusses how health plans can combine consumer, employer, geographic and healthcare data to identify growth opportunities, reduce...
In this episode, Bob Tavernier, Solutions Executive at Quest Analytics®, discusses how health plans can leverage AI, provider data and strategic partnerships to improve network accuracy, strengthen regulatory compliance...
In this episode, Martina Lee Strickland, Head of Marketing, PR and Brand at Clever Care Health Plan, joins the podcast to discuss the importance of building trust when serving underserved communities. She also shares...